Loading...
Please wait, while we are loading the content...
Similar Documents
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
| Content Provider | Scilit |
|---|---|
| Author | Bartlett, Nancy Costello, Brian A. LaPlant, Betsy R. Ansell, Stephen M. Kuruvilla, John G. Reeder, Craig B. Thye, Lim S. Anderson, Daniel M. Krysiak, Kilannin Ramirez, Cody Qi, Jing Siegel, Barry A. Griffith, Malachi Griffith, Obi L. Gomez, Felicia Fehniger, Todd A. |
| Copyright Year | 2018 |
| Description | Key Points Ibrutinib has modest activity in FL with low response rates in rituximab-refractory patients. CARD11 mutations predict for lack of response to ibrutinib. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757691/pdf |
| Ending Page | 190 |
| Page Count | 9 |
| Starting Page | 182 |
| DOI | 10.1182/blood-2017-09-804641 |
| Journal | Blood |
| Issue Number | 2 |
| Volume Number | 131 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2018-01-11 |
| Access Restriction | Open |
| Subject Keyword | Hematology Lymphoma Rituximab Follicular Consortium Card11 Relapsed Or Refractory Agent Ibrutinib Journal: Blood (Vol- 61, Issue- 2) |
| Content Type | Text |
| Resource Type | Article |